Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
2.040
-0.110 (-5.12%)
At close: Oct 23, 2026, 4:00 PM EDT
2.030
-0.010 (-0.49%)
After-hours: Oct 23, 2026, 7:58 PM EDT
Jaguar Health Revenue
Jaguar Health had revenue of $1.23M in the quarter ending June 30, 2026, a decrease of -58.88%. This brings the company's total for the last twelve months to $27.82M, up 135.52% year-over-year. In the year 2025, Jaguar Health had annual revenue of $11.51M, down -1.52%. That makes Jaguar Health the 31,807th largest company in the world by revenue and 4,188th in the United States.
Revenue (ttm)
$27.82M
Revenue Growth
+135.52%
P/S Ratio
0.04
Revenue / Employee
$591,809
Employees
47
Market Cap
1.06M
Revenue by Segment
- Human Health 11.16M 96.9%
- Animal Health 353.00K 3.1%
Fiscal year ended Dec 31, 2025 See the full Jaguar Health breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.51M | -178.00K | -1.52% |
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
| Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
| Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
| Dec 31, 2015 | 258.38K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 4.31M |
| Onconetix | 645.82K |
| Endovia Health Sciences | 32.09K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
JAGX News
- 1 day ago - Jaguar Health files $75M mixed securities shelf - TheFly
- 1 day ago - Jaguar Health Registration statement: Registration filing - Filings
- 2 days ago - Jaguar says crofelemer shows benefit for IF in congenital enteropathy disorder - TheFly
- 2 days ago - Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder - Accesswire
- 9 days ago - Jaguar Health sets ex-dividend date for Series R preferred stock dividend - TheFly
- 9 days ago - Jaguar Health Provides Update Regarding Special Stock Dividend - Accesswire
- 9 days ago - Jaguar Health’s Napo provides recap of preliminary results on crofelemer powder - TheFly
- 9 days ago - Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer - Accesswire